Papillary Renal Cell Carcinoma

Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape

“…The goals of therapy are dependent on the extent of the disease. Treatment options for localized PRCC include surgical removal (partial or radical nephrectomy), ablation (cryoablation, radiofrequency ablation, or microwave ablation), or active surveillance, similar to the treatment options for localized clear cell RCC (2,12). Small PRCC (4 cm) confined to the kidney can be managed with nephron-sparing surgery (partial nephrectomy), as it produces satisfactory patient outcomes (12,14).…”

“…Treatment options for localized PRCC include surgical removal (partial or radical nephrectomy), ablation (cryoablation, radiofrequency ablation, or microwave ablation), or active surveillance, similar to the treatment options for localized clear cell RCC (2,12). Small PRCC (4 cm) confined to the kidney can be managed with nephron-sparing surgery (partial nephrectomy), as it produces satisfactory patient outcomes (12,14). Radical nephrectomy may be performed depending on the extent of disease, tumor location, presence of metastases, as well as additional patient-specific factors including patient comorbidities and overall health status.…”

“…Radical nephrectomy may be performed depending on the extent of disease, tumor location, presence of metastases, as well as additional patient-specific factors including patient comorbidities and overall health status. Surgical resection is typically the definitive therapy for localized disease without metastases as it offers the greatest chance of cure (12,14,15).…”

“…Systemic therapy is typically administered as a single therapy or in combination with other agents. Available therapies include programmed cell death protein 1 (PD-1) checkpoint inhibitors (nivolumab and pembrolizumab), programmed cell death ligand 1 (PD-L1) Product-limit survival estimates with number of subjects at risk and 95% confidence limits Product-limit survival estimates with number of subjects at risk and 95% confidence limits Product-limit survival estimates with number of subjects at risk and 95% confidence limits Product-limit survival estimates with number of subjects at risk and 95% confidence limits Product-limit survival estimates with number of subjects at risk and 95% confidence limits Product-limit survival estimates with number of subjects at risk and 95% confidence limits Although recent WHO reclassifications have a single PRCC category, existing literature classifies PRCC into Types 1 and 2, primarily based on histopathology (12,16,24). Type 1 PRCC is characterized by basophilic cells, small nuclei, and a single layer of cuboidal or columnar epithelial cells (2).…”

“…It is typically confined to the kidney and is associated with a good prognosis. Type 1 PRCC is associated with hereditary renal cancer syndrome (germline MET) and gains in chromosomes 7 and 17 along with gains in chromosomes 2, 3, 12, 16, and 20 that occur less often (12,18,20,25). Therapeutic agents such as crizotinib, savolitinib, and cabozantinib show promising inhibitor properties against MET, which are useful in treating type 1 PRCC (20).…”